HUM's Star Ratings recovery is set to show early progress, but October's CMS release will test its MA turnaround and path to a 2028 margin target.

UNH's improving medical costs, higher EPS estimates and capital returns support its recovery, but regulatory risks remain.

CVS delivers strong Q2 growth and raises 2026 targets, but Caremark pressures and medical costs are likely to shape its next move.

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HUM's HealthStream deal backs 1,000 caregiver scholarships and new tools to improve recruitment and retention in Indiana.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.

TDOC tops adjusted earnings estimates despite a revenue miss, as Integrated Care and international growth help cushion BetterHelp weakness and a lower 2026 outlook.